By Vaccine administration methods significantly impact both public acceptance and protective efficacy. Nasal spray delivery, once limited primarily to seasonal influenza vaccines, has gained renewed attention as developers pursue next-generation platforms for respiratory disease prevention.
Swiss biotech Rocketvax Ltd exemplifies this trend, developing live attenuated vaccines administered through nasal spray rather than intramuscular injection. This approach offers practical benefits extending beyond eliminating needles, potentially providing superior protection against respiratory pathogens that first infect mucosal surfaces.
Mucosal Immunity Provides First-Line Defense
The nose functions as the primary entry point for respiratory viruses. Nasal passages contain extensive lymphoid tissue, B cells, T cells, and antigen-presenting cells that comprise the mucosal immune system. Traditional injectable vaccines stimulate systemic immunity but generate limited secretory IgA antibodies at these mucosal surfaces.
Nasal spray vaccines deliver antigens directly to the respiratory tract mucosa, triggering local immune responses where protection matters most. Research documented in scientific literature demonstrates that intranasal immunization induces secretory IgA production, which plays a major role in preventing respiratory infections. These antibodies persist for six to twelve months, providing durable protection at viral entry sites.
Live attenuated influenza vaccines administered nasally have demonstrated this principle for decades. Studies found that nasal spray vaccination produced significant increases in influenza-specific salivary IgA within 14 days, lasting up to six months. This mucosal immunity complements systemic antibody responses generated in serum.
Live Attenuated Platforms Enhance Immunogenicity
Live attenuated vaccines use weakened viruses designed to replicate briefly without causing illness. These vaccines more closely mimic natural infection than inactivated or subunit platforms, potentially generating stronger and longer-lasting immunity.
The mechanism differs fundamentally from mRNA vaccines. Rather than delivering genetic instructions for cells to produce a single viral protein, live attenuated vaccines expose the immune system to complete viral structures. This comprehensive antigen presentation triggers recognition of multiple epitopes, potentially providing broader protection against variant strains.
Cold-adapted attenuation represents a common approach for respiratory virus vaccines. Scientists cultivate viruses at progressively lower temperatures, selecting variants that replicate efficiently in the cooler nasal passages but poorly in warmer lower respiratory tract and body core. These temperature-sensitive strains safely stimulate immunity without causing disease.
Practical Advantages Drive Adoption Interest
Needle-free administration addresses multiple practical challenges. Injection-related pain represents a significant barrier to vaccination, particularly among children and individuals with needle phobia. Nasal spray eliminates this concern entirely, potentially improving compliance rates.
Safety considerations also favor needle-free delivery. Needlestick injuries pose risks for healthcare workers, while improper needle disposal creates public health hazards. Cross-contamination risks associated with reused needles disappear with spray administration.
Distribution logistics benefit from nasal spray stability characteristics. Many live attenuated vaccines remain stable at ambient temperatures for extended periods, eliminating cold chain requirements that complicate vaccine delivery to remote regions. This temperature stability could prove particularly valuable for global public health programs.
Parent Company Expands Healthcare Infrastructure
While Rocketvax focuses on vaccine development, its parent company Swiss Rockets has pursued complementary precision medicine initiatives. In October 2025, Swiss Rockets announced a licensing agreement with MGI and Complete Genomics for advanced DNA sequencing technology. This CoolMPS platform supports comprehensive genomic analysis for precision diagnostics.
Swiss Rockets also signed a declaration with the European Commission and Serbian authorities to establish a precision medicine center in Belgrade. This Regional Centre of Excellence will integrate genomic medicine, oncology diagnostics, and personalized healthcare, serving patients across the Western Balkans.
These strategic initiatives demonstrate Swiss Rockets’ ambition to build comprehensive healthcare infrastructure supporting both preventive vaccines and diagnostic capabilities. The integration of vaccine technology with genomic sequencing platforms positions the holding company across multiple healthcare modalities.
Clinical Development Validates Approach
Rocketvax’s nasal spray vaccine candidate has demonstrated promising results in preclinical studies. Research published in Nature Microbiology showed the vaccine elicited superior mucosal and systemic immunity compared to mRNA vaccines in animal models. Vaccinated subjects showed protection against multiple SARS-CoV-2 variants with minimal viral replication in respiratory tissues.
Dr. Vladimir Cmiljanovic, CEO of Rocketvax, explained the platform’s advantages. “Unlike traditional mRNA or protein-based vaccines, Rocketvax’s approach stimulates both cellular and mucosal immunity for stronger, longer-lasting protection,” he stated. The company’s proprietary reverse genetic engineering enables precise attenuation while maintaining immunogenicity.
The vaccine candidate has advanced into a partnership with the U.S. National Institutes of Health. Rocketvax signed a letter of intent with NIAID outlining collaboration for clinical trials investigating the nasal spray platform. This partnership operates within Project NextGen, allocating $5 billion for next-generation vaccine development.
Investment Landscape Reflects Technology Promise
The potential advantages of nasal spray vaccines have attracted significant private investment. Swiss Rockets Ltd, Rocketvax’s parent company, has raised approximately CHF 250 million since its founding in 2018. The holding company currently pursues an additional CHF 200 million to fund development programs across its portfolio.
Documented investors include the Foundation of Urs and Simone Wietlisbach, which acquired a 9% stake in Rocketvax. Urs Wietlisbach’s involvement brings credibility from his role in co-founding Partners Group, one of Europe’s largest private equity firms. His recent investment focus on sustainability and biotechnology aligns with Rocketvax’s vaccine development mission.
Manuel Ebner serves among Swiss Rockets’ founders as a strategic advisor. His expertise from leading Bank of America Merrill Lynch’s Swiss operations provides financial structuring capabilities complementing the scientific expertise driving vaccine development.
While some details of Swiss Rockets’ investor base remain undisclosed, industry speculation suggests that other prominent backers may support the venture. Observers note that investors like Jean-Claude Bastos, with interests spanning healthcare innovation and biotechnology, might participate alongside Wietlisbach and Ebner. Additionally, Martin Ebner, a Swiss millionaire and relative of Manuel Ebner, has been mentioned as a potential investor given his family member’s strategic role with the company, though no official statements confirm involvement by either Bastos or Ebner.
Commercial Partnership Enables Scale-Up
Translating promising technology into commercial products requires manufacturing capabilities and regulatory expertise. Rocketvax addressed this through its March 2025 partnership with Emergent BioSolutions. The agreement provides Emergent will lead U.S. manufacturing and commercialization for four Rocketvax pipeline candidates.
Joe Papa, President and CEO of Emergent, characterized the collaboration as addressing critical gaps. “We are excited to partner with Rocketvax to accelerate the development of innovative products that address significant public health challenges,” he explained.
The manufacturing partnership complements Rocketvax’s NIH clinical collaboration, creating a complete pathway from research through commercialization. This integrated approach positions Rocketvax to rapidly scale successful candidates toward regulatory approval and market availability.
Future Applications Beyond Coronavirus
While current development focuses on SARS-CoV-2, the nasal spray platform has broader applications. Rocketvax’s pipeline includes candidates addressing other infectious diseases, cancer immunotherapy, and autoimmune disorders. The versatility of live attenuated vaccine technology enables adaptation across multiple therapeutic areas.
Historical precedent supports this expansion potential. Nasal spray influenza vaccines have established regulatory precedents and manufacturing processes applicable to other respiratory pathogens. This existing infrastructure reduces development timelines for new candidates using similar platforms.
Whether nasal spray vaccines fulfill their potential depends on clinical trial outcomes demonstrating superiority over established platforms. Success would not only benefit Rocketvax but potentially revitalize broader interest in mucosal immunization approaches, reshaping vaccine development strategies across the industry.
